Rothschild Investment LLC’s Corcept Therapeutics CORT Stock Holding History

Rothschild Investment LLC’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06M	Buy	12,195 +11,470	+1,582%	+$693K	0.04%	400
2026 Q1	$29.2K	Sell	725 -114	-14%	-$4.26K	﹤0.01%	1276
2025 Q4	$29.2K	Sell	839 -116	-12%	-$9.11K	﹤0.01%	1198
2025 Q3	$79.4K	Buy	+955	New	+$69.1K	﹤0.01%	864
2025 Q2	–	Sell	-125	Closed	-$14.3K	–	3058
2025 Q1	$14.3K	Buy	125 +40	+47%	+$2.44K	﹤0.01%	1084
2024 Q4	$4.28K	Buy	85 +10	+13%	+$524	﹤0.01%	1406
2024 Q3	$3.47K	Buy	75 +40	+114%	+$1.42K	﹤0.01%	1440
2024 Q2	$1.14K	Buy	35 +30	+600%	+$822	﹤0.01%	1594
2024 Q1	$126	Buy	+5	New	+$118	﹤0.01%	2056

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rothschild Investment LLC's CORT Position: Q2 2026 in Review

Rothschild Investment LLC increased its Corcept Therapeutics (CORT) stake by 1,582% in Q2 2026, buying an estimated $693K and bringing the position to 12,195 shares worth $1.06M. The position accounts for 0.04% of the portfolio, ranked #400.

Rothschild Investment LLC first reported a position in CORT in Q1 2024 and has held it in 9 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Rothschild Investment LLC held 12,195 shares of Corcept Therapeutics worth $1.06M as of Q2 2026.
Rothschild Investment LLC bought 11,470 Corcept Therapeutics shares in Q2 2026, an estimated $693K.
Corcept Therapeutics made up 0.04% of Rothschild Investment LLC's portfolio in Q2 2026, its #400 holding.
Rothschild Investment LLC first reported a position in Corcept Therapeutics in Q1 2024 and has held it in 9 quarters since.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.